Analyst: All of the building blocks for Genmab's upgrade were in place

Novartis, Horizon and Janssen have all reported good results for the drugs from which Genmab receives royalties. It therefore doesn't come as a surprise that the company has chosen to upgrade its financial huidance shortly before the release of its report, says an analyst at Sydbank.
Photo: Lars Møller / Genmab / PR
Photo: Lars Møller / Genmab / PR

Over the past 14 days, news of drug sales surpassing expectations has trickled in from Genmab's partners, who pay royalties from the sales of Genmab-developed drugs. It should therefore come as no surprise that the company upgraded its financial expectations on Thursday night, says Senior Analyst at Sydbank Søren Løntoft Hansen.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading